Beyond ATRX: The heterogeneous basis of Alternative Lengthening of Telomeres in osteosarcoma.
Cancer GenetJun 2, 2026 (epub)
Clinical ResearchOncology (Medical)
Tomas Goncalves, Natalie S Mattis, Amy F M Mitchell et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined the prevalence of the alternative lengthening of telomeres (ALT) in osteosarcoma using patient-derived samples and genomic datasets. Among 342 tumors analyzed, ALT activity was found in 62.9% of cases, while canonical genetic alterations like ATRX or DAXX mutations were much less frequent. The study highlights the biological heterogeneity of ALT mechanisms in osteosarcoma.
Key findings
- ALT activity was identified in 62.9% of osteosarcoma cases across seven studies.
- Mutations in ATRX or DAXX and amplification of TOP3A occurred at lower frequencies.
- There is a significant discrepancy between ALT prevalence and canonical genetic alterations.
- Non-mutational mechanisms may drive ALT activation in osteosarcoma.
Why it matters
Understanding the prevalence and mechanisms of ALT in osteosarcoma is crucial for developing targeted therapies. The findings suggest that current genetic assessments may not fully capture the complexity of telomere maintenance in these tumors.